Virus chimeras for gene therapy, vaccination, and oncolysis: Adenoviruses and beyond

Trends in Molecular Medicine

Volumn 18, Issue 7, 2012, Pages 365-376

  Kaufmann, Johanna K ^a   Nettelbeck, Dirk M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Adenovirus; Chimeric virus; Gene delivery; Gene transfer vector; Oncolytic virus; Viral tropism; Virus capsid

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 9; ONCOLYTIC VIRUS; POLIOMYELITIS VACCINE; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ADENOVIRUS; CANINE DISTEMPER MORBILLIVIRUS; CELLULAR IMMUNITY; CHIMERA; GENE EXPRESSION; GENE THERAPY; GLIOBLASTOMA; HEMOPHILIA B; HUMAN; HUMAN ADENOVIRUS 5; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POXVIRUS; REGULATORY SEQUENCE; REVIEW; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; DNA VIRUSES; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; RECOMBINATION, GENETIC; VACCINES, SYNTHETIC; VIRUSES;

ADENOVIRIDAE; MIRIDAE;

EID: 84863112893     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.04.008     Document Type: Review

References (95)

1. Bowser B.S., et al. Human papillomavirus type 18 chimeras containing the L2/L1 capsid genes from evolutionarily diverse papillomavirus types generate infectious virus. Virus Res. 2011, 160:246-255.
2. Stone D., et al. Comparison of adenoviruses fromspecies B, C, E, and F after intravenous delivery. Mol. Ther. 2007, 15:2146-2153.
3. Stevenson S.C., et al. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J. Virol. 1995, 69:2850-2857.
4. Krasnykh V.N., et al. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 1996, 70:6839-6846.
5. Volk A.L., et al. Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol. Ther. 2003, 2:511-515.
6. Rivera A.A., et al. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther. 2004, 11:1694-1702.
7. Shayakhmetov D.M., et al. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J. Virol. 2003, 77:3712-3723.
8. Shayakhmetov D.M., Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 2000, 74:10274-10286.
9. Seki T., et al. Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo. Gene Ther. 2002, 9:1101-1108.
10. Wu E., et al. Flexibility of the adenovirus fiber is required for efficient receptor interaction. J. Virol. 2003, 77:7225-7235.
11. Breidenbach M., et al. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum. Gene Ther. 2004, 15:509-518.
12. Gall J., et al. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 1996, 70:2116-2123.
13. Ni S., et al. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther. 2006, 13:1072-1081.
14. Kuhlmann K.F., et al. Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma. Cancer Gene Ther. 2009, 16:585-597.
15. Miyazawa N., et al. Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J. Virol. 1999, 73:6056-6065.
16. Schoggins J.W., Falck-Pedersen E. Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity. J. Virol. 2006, 80:10634-10644.
17. Sakurai F., et al. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35. J. Control. Release 2010, 148:212-218.
18. Schoggins J.W., et al. Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo. J. Virol. 2003, 77:1039-1048.
19. Nicol C.G., et al. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol. Ther. 2004, 10:344-354.
20. Hesse A., et al. Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. J. Virol. 2007, 81:2688-2699.
21. Kashentseva E.A., et al. Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody. J. Mol. Biol. 2009, 388:443-461.
22. Ranki T., Hemminki A. Serotype chimeric human adenoviruses for cancer gene therapy. Viruses 2010, 2:2196-2212.
23. He X., et al. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Hum. Gene Ther. 2011, 22:283-292.
24. Koski A., et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol. Ther. 2010, 18:1874-1884.
25. Pesonen S., et al. Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol. 2010, 49:117-119.
26. Pesonen S., et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther. 2010, 17:892-904.
27. Glasgow J.N., et al. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology 2004, 324:103-116.
28. Nakayama M., et al. An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice. Virology 2006, 350:103-115.
29. Grellier E., et al. A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors. Mol. Cancer 2011, 10:105.
30. van Beusechem V.W., et al. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther. 2000, 7:1940-1946.
31. Krasnykh V., et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol. 2001, 75:4176-4183.
32. Tsuruta Y., et al. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Clin. Cancer Res. 2007, 13:2777-2783.
33. Murakami M., et al. An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populations. Virology 2010, 407:196-205.
34. Van Vliet K.M., et al. The role of the adeno-associated virus capsid in gene transfer. Methods Mol. Biol. 2008, 437:51-91.
35. Asokan A., et al. The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 2012, 20:699-708.
36. Asokan A., et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 2010, 28:79-82.
37. Burns J.C., et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:8033-8037.
38. Morizono K., et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 2005, 11:346-352.
39. Carpentier D.C., et al. Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope glycoprotein. Gene Ther. 2011, 10.1038/gt.2011.124.
40. Enkirch T., et al. Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins. Gene Ther. 2012, 10.1038/gt.2011.209.
41. Funke S., et al. Targeted cell entry of lentiviral vectors. Mol. Ther. 2008, 16:1427-1436.
42. Funke S., et al. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther. 2009, 16:700-705.
43. Ayala-Breton C., et al. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum. Gene Ther. 2012, 10.1089/hum.2011.146.
44. Ungerechts G., et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol. Ther. 2007, 15:1991-1997.
45. Wu H., et al. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J. Virol. 2002, 76:12775-12782.
46. Bradley R.R., et al. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol. 2012, 86:625-629.
47. Roberts D.M., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441:239-243.
48. Tian X., et al. Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res. 2011, 160:214-220.
49. Bradley R.R., et al. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J. Virol. 2012, 86:1267-1272.
50. Nanda A., et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J. Virol. 2005, 79:14161-14168.
51. Sarkioja M., et al. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther. 2008, 15:921-929.
52. Sharma A., et al. Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther. 2010, 17:634-642.
53. Rogee S., et al. Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response. Gene Ther. 2010, 17:880-891.
54. Miest T.S., et al. Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol. Ther. 2011, 19:1813-1820.
55. Huard J., et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 1995, 2:107-115.
56. Alemany R., et al. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 2000, 81:2605-2609.
57. Nakamura T., et al. Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J. Virol. 2003, 77:2512-2521.
58. Denby L., et al. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum. Gene Ther. 2004, 15:1054-1064.
59. Di Paolo N.C., et al. Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo. J. Virol. 2007, 81:12249-12259.
60. Shayakhmetov D.M., et al. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 2005, 79:7478-7491.
61. Waddington S.N., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132:397-409.
62. Alba R., et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009, 114:965-971.
63. Short J.J., et al. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol. Cancer Ther. 2010, 9:2536-2544.
64. Zhang Z., et al. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum. Gene Ther. 2011, 22:1137-1142.
65. Alba R., et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010, 116:2656-2664.
66. Gimenez-Alejandre M., et al. Coagulation factors determine tumor transduction in vivo. Hum. Gene Ther. 2008, 19:1415-1419.
67. Corjon S., et al. Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction. PLoS ONE 2011, 6:e18205.
68. Khare R., et al. Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J. Virol. 2012, 86:2293-2301.
69. Lyons M., et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther. 2006, 14:118-128.
70. Carlisle R.C., et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009, 113:1909-1918.
71. Seiradake E., et al. The cell adhesion molecule " CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 2009, 5:e1000277.
72. Kuhn I., et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 2008, 3:e2409.
73. Wong H.H., et al. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol. Ther. 2012, 20:306-316.
74. Shah A.C., et al. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther. 2007, 14:1045-1054.
75. Ochiai H., et al. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin. Cancer Res. 2004, 10:4831-4838.
76. Gallaher S.D., et al. Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector. J. Virol. 2009, 83:3249-3257.
77. Sun Y., et al. A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever. Vaccine 2011, 29:8364-8372.
78. Kubo S., et al. Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo. Mol. Ther. 2011, 19:76-82.
79. Lam P.Y., Breakefield X.O. Hybrid vector designs to control the delivery, fate and expression of transgenes. J. Gene Med. 2000, 2:395-408.
80. Vesikari T., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 2006, 354:23-33.
81. Guy B., et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
82. Grimm D., et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 2008, 82:5887-5911.
83. Hickey R.D., et al. Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. Hepatology 2011, 54:1351-1359.
84. Dobrikova E.Y., et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol. Ther. 2008, 16:1865-1872.
85. Gromeier M., et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6803-6808.
86. Toyoda H., et al. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res. 2007, 67:2857-2864.
87. Cello J., et al. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. J. Med. Virol. 2008, 80:352-359.
88. Dobrikova E.Y., et al. Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. J. Virol. 2012, 86:2750-2759.
89. Goetz C., Gromeier M. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev. 2010, 21:197-203.
90. Matthews Q.L., et al. HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS ONE 2010, 5:e11815.
91. Clark H.F., et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J. Infect. Dis. 1996, 174(Suppl. 1):S73-S80.
92. Heaton P.M., et al. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J. Infect. Dis. 2005, 192(Suppl. 1):S17-S21.
93. Guy B., et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
94. Zhao L., et al. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18. Virol. J. 2011, 8:302.
95. Mourez T., et al. A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells. Virology 2011, 419:117-125.